BeiGene, Ltd.
BGNEDrugs in Pipeline
45
Phase 3 Programs
12
Upcoming Catalysts
11
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
11 upcoming, 1 past
Tislelizumab
Urothelial Carcinoma
5-fluorouracil
Resectable Esophageal Squamous Cell Carcinoma
Pamiparib capsule
Ovarian Cancer
Cisplatin injection
Non Small Cell Lung Cancer
Zanubrutinib
Refractory Mantle Cell Lymphoma
BGB-3111
Waldenström's Macroglobulinemia
Ociperlimab
Limited Stage Small Cell Lung Cancer
Sonrotoclax
Chronic Lymphocytic Leukemia
Gemcitabine Hydrochloride
Urothelial Carcinoma
BGB-16673
Chronic Lymphocytic Leukemia
Adjuvant chemotherapy
Colorectal Cancer
Fluorouracil (5-FU)
Esophageal Squamous Cell Carcinoma (ESCC)
Nab paclitaxel
Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC)
BGB-45035
Rheumatoid Arthritis
BGB-DXP593
Covid19
BGB-290
HER2-negative Breast Cancer
BAT1706
Advanced Hepatocellular Carcinoma
Sitravatinib
Carcinoma, Hepatocellular
Zanidatamab
Breast Cancer
idarubicin/daunorubicin
Acute Myeloid Leukemia
Tislelizumab is a fully humanized monoclonal antibody specific for human PD-1
Esophageal Squamous Cell Carcinoma (ESCC)
HIPEC
Gastric Cancer
Zanubrutinib Pill
Leukemia, Lymphocytic, Chronic, B-Cell
HAIC+TAE
Intrahepatic Cholangiocarcinoma
5-FU
Esophageal Squamous Cell Carcinoma, Gastric Carcinoma, Gastroesophageal Junction Carcinoma
Alcestobart
Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
adjuvant tislelizumab and chemotherapy for MRD+ patients
NSCLC
Mavrostobart (PT199)
Non Small Cell Lung Cancer
PARP Inhibitor BGB-290
IDH1 Mutation
Luteinizing Hormone Releasing Hormone
Prostate Cancer
Zanubrutinib Oral Product
Monoclonal Gammopathy of Uncertain Significance
Glofitamab
Lymphoma, Mantle-Cell
LBL-007
Non-small Cell Lung Cancer
Tislelizumab + Anlotinib
SCLC, Limited Stage
SX-682
Pancreatic Cancer
Tislelizumab (BGB-A317)
MSI-H/dMMR Solid Tumors
BGB-10188
Chronic Lymphocytic Leukemia
BGB-A445
Non-Small Cell Lung Cancer
BGB-A425
Locally Advanced or Metastatic Solid Tumors for Phase 1,Dose Escalation and Phase 2 Safety Lead-in, HNSCC, NSCLC and RCC Participants for Phase 2
lenvatinib
Advanced Solid Tumor
Supportive Care
COVID-19 Pulmonary Complications
BGB-11417
Mantle Cell Lymphoma
Chemotherapy Doublet
Esophageal Cancer
Fruquintinib
Advanced Solid Tumors
Pamiparib
Brain and Central Nervous System Tumors
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Tislelizumab | Phase 3 | Urothelial Carcinoma | - | - |
5-fluorouracil | Phase 3 | Resectable Esophageal Squamous Cell Carcinoma | - | - |
Pamiparib capsule | Phase 3 | Ovarian Cancer | - | - |
Cisplatin injection | Phase 3 | Non Small Cell Lung Cancer | - | - |
Zanubrutinib | Phase 3 | Refractory Mantle Cell Lymphoma | - | - |
BGB-3111 | Phase 3 | Waldenström's Macroglobulinemia | - | - |
Ociperlimab | Phase 3 | Limited Stage Small Cell Lung Cancer | - | - |
Sonrotoclax | Phase 3 | Chronic Lymphocytic Leukemia | - | - |
Gemcitabine Hydrochloride | Phase 3 | Urothelial Carcinoma | - | - |
BGB-16673 | Phase 3 | Chronic Lymphocytic Leukemia | - | - |
Adjuvant chemotherapy | Phase 3 | Colorectal Cancer | - | - |
Fluorouracil (5-FU) | Phase 3 | Esophageal Squamous Cell Carcinoma (ESCC) | - | - |
Nab paclitaxel | Phase 2 | Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC) | - | - |
BGB-45035 | Phase 2 | Rheumatoid Arthritis | - | - |
BGB-DXP593 | Phase 2 | Covid19 | - | - |
BGB-290 | Phase 2 | HER2-negative Breast Cancer | - | - |
BAT1706 | Phase 2 | Advanced Hepatocellular Carcinoma | - | - |
Sitravatinib | Phase 2 | Carcinoma, Hepatocellular | - | - |
Zanidatamab | Phase 2 | Breast Cancer | - | - |
idarubicin/daunorubicin | Phase 2 | Acute Myeloid Leukemia | - | - |
Tislelizumab is a fully humanized monoclonal antibody specific for human PD-1 | Phase 2 | Esophageal Squamous Cell Carcinoma (ESCC) | - | - |
HIPEC | Phase 2 | Gastric Cancer | - | - |
Zanubrutinib Pill | Phase 2 | Leukemia, Lymphocytic, Chronic, B-Cell | - | - |
HAIC+TAE | Phase 2 | Intrahepatic Cholangiocarcinoma | - | - |
5-FU | Phase 2 | Esophageal Squamous Cell Carcinoma, Gastric Carcinoma, Gastroesophageal Junction Carcinoma | - | - |
Alcestobart | Phase 2 | Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer | - | - |
adjuvant tislelizumab and chemotherapy for MRD+ patients | Phase 2 | NSCLC | - | - |
Mavrostobart (PT199) | Phase 2 | Non Small Cell Lung Cancer | - | - |
PARP Inhibitor BGB-290 | Phase 2 | IDH1 Mutation | - | - |
Luteinizing Hormone Releasing Hormone | Phase 2 | Prostate Cancer | - | - |
Zanubrutinib Oral Product | Phase 2 | Monoclonal Gammopathy of Uncertain Significance | - | - |
Glofitamab | Phase 2 | Lymphoma, Mantle-Cell | - | - |
LBL-007 | Phase 2 | Non-small Cell Lung Cancer | - | - |
Tislelizumab + Anlotinib | Phase 2 | SCLC, Limited Stage | - | - |
SX-682 | Phase 2 | Pancreatic Cancer | - | - |
Tislelizumab (BGB-A317) | Phase 2 | MSI-H/dMMR Solid Tumors | - | - |
BGB-10188 | Phase 2 | Chronic Lymphocytic Leukemia | - | - |
BGB-A445 | Phase 2 | Non-Small Cell Lung Cancer | - | - |
BGB-A425 | Phase 2 | Locally Advanced or Metastatic Solid Tumors for Phase 1,Dose Escalation and Phase 2 Safety Lead-in, HNSCC, NSCLC and RCC Participants for Phase 2 | - | - |
lenvatinib | Phase 2 | Advanced Solid Tumor | - | - |
Supportive Care | Phase 2 | COVID-19 Pulmonary Complications | - | - |
BGB-11417 | Phase 2 | Mantle Cell Lymphoma | - | - |
Chemotherapy Doublet | Phase 2 | Esophageal Cancer | - | - |
Fruquintinib | Phase 2 | Advanced Solid Tumors | - | - |
Pamiparib | Phase 2 | Brain and Central Nervous System Tumors | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in BeiGene, Ltd.'s drug pipeline?→
CatalystAlert tracks 45 drug candidates in BeiGene, Ltd.'s (BGNE) pipeline across Phase 3, Phase 2. Its lead program is Tislelizumab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is BeiGene, Ltd.'s next FDA catalyst?→
BeiGene, Ltd.'s (BGNE) next tracked catalyst is a Phase 2 expected September 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BGNE biotech catalysts?→
Add BGNE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow BeiGene, Ltd.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.